Canntab Therapeutics

CANNTAB ENGAGES HAMISH SUTHERLAND AS STRATEGIC ADVISOR
"to work with Canntab and develop additional sales and distribution channels for the extensive suite of Canntab’s products and to assist Canntab in reaching strategic partnerships in the Cannabis industry."

https://canntab.ca/press-releases/

Canntab Therapeutics Dedicated to the research and development of hard pill, therapeutic formulations of cannabis.

Our CFO and co-founder Richard Goldstein joined Christine Corrado on Proactive to talk about our new affiliate agreement with OnPharm-United, a 600 plus network of independent pharmacy owners throughout the Province of Ontario.
https://www.youtube.com/watch?v=uINZnQ394zY&ab_channel=Proactive

Canntab Therapeutics inks affiliate deal with independent pharmacy owners in Ontario Canntab Therapeutics Ltd CFO Richard Goldstein tells Proactive that it has entered into an affiliate agreement with OnPharm-United, a 600-plus network of ind...

Our CFO and co-founder Richard Goldstein, and our CEO Larry Latowsky, joined Steve Darling on Proactive to talk about our Indigenous Op**te and Illicit Drug Crisis Plan.

https://www.youtube.com/watch?v=G-inpEsYWg0

Canntab Therapeutics signs what it calls an Historic Deal with First Nations to battle opioid Crisis Canntab Therapeutics CFO Richard Goldstein and CEO Larry Latowsky joined Steve Darling from Proactive to share the company has announced a strategic planning...

CANNTAB SIGNS HISTORIC AGREEMENT WITH FIRST NATIONS GROWERS GP INC. TO ADDRESS THE OP**TE AND ILLICIT DRUG CRISIS AFFECTING INDIGENOUS PEOPLES THROUGHOUT CANADA

https://canntab.ca/press-releases/

Canntab Therapeutics Dedicated to the research and development of hard pill, therapeutic formulations of cannabis.

CANNTAB ANNOUNCES CLOSING OF CONVERTIBLE DEBENTURE PRIVATE PLACEMENT, WARRANT EXPIRY EXTENSION AND CORPORATE UPDATE.

https://canntab.ca/press-releases/

Canntab Therapeutics Dedicated to the research and development of hard pill, therapeutic formulations of cannabis.

Our Online Store is Open! We've officially launched our online e-commerce platform.

Whether you need a medical document, or you already have one, our team is here to help.

https://Canntab.ca/Get-Started/

Canntab Therapeutics Dedicated to the research and development of hard pill, therapeutic formulations of cannabis.

Our CFO, Richard Goldstein, had the chance to talk with Steve Darling at Proactive about our latest shipments to the OCS and Australia.

Check out the full interview here,

https://www.youtube.com/watch?v=LOK5jf8v8lc

Canntab Therapeutics able to deliver 1st shipment to Ontario Cannabis Store and 2nd to Australia Canntab Therapeutics CFO Richard Goldstein joined Steve Darling from Proactive to share news the company has completed its first shipment of 5 mg THC tablets...

CANNTAB DELIVERS 1st SHIPMENT TO THE ONTARIO CANNABIS STORE AND 2nd SHIPMENT TO AUSTRALIA



https://canntab.ca/press-releases/

Canntab Therapeutics Dedicated to the research and development of hard pill, therapeutic formulations of cannabis.

CANNTAB ENTERS INTO STRATEGIC PARTNERSHIP TO PROVIDE ALTERNATIVES TO OP**TES THROUGH LEVITEE CLINICS



https://canntab.ca/press-releases

Canntab Therapeutics Dedicated to the research and development of hard pill, therapeutic formulations of cannabis.

Press Release: CANNTAB ANNOUNCES AGREEMENT WITH PATHWAY HEALTH

Pathway Health is one of the largest providers of out-of-hospital pain management services in Canada.

https://canntab.ca/press-releases/

Canntab Therapeutics Dedicated to the research and development of hard pill, therapeutic formulations of cannabis.

Now it's easier to send Canntab Therapeutics a message.

PRESS RELEASE: CANNTAB RECEIVES EXPORT LICENSE APPROVAL FROM HEALTH CANADA

Canntab can now fulfill the purchase order received from its Australian partner, Cann Global Limited.

https://ca.finance.yahoo.com/news/canntab-receives-export-license-approval-113000901.html

**p

Canntab Receives Export License Approval from Health Canada Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that Health Canada has granted the company an Export License.

NEW ARTICLE: As Australia opens to cannabis, Canntab’s (PILL.C) tech might just claim the box seat!

https://equity.guru/2021/03/18/as-australia-opens-to-cannabis-canntabs-pill-c-tech-might-just-claim-the-box-seat/

Our CFO Richard Goldstein got a chance to catch up with Jodie Vance at Equity Guru. Watch the full video here,

https://www.youtube.com/watch?v=bT7hllaYyy8

First Glance with Jody Vance (E38): Update from Canntab Therapeutics (PILL.C) CFO Richard Goldstein About Canntab:Canntab Therapeutics is a Canadian biopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid ...

Our CFO Richard Goldstein was on Proactive discussing our latest patent, and our deal with Cann Global in Australia.

Watch the full video here,

https://ca.proactiveinvestors.com/companies/news/943409/canntab-therapeutics-granted-3rd-patent-while-also-taking-part-in-large-medical-cannabis-study-943409.html

Canntab Therapeutics granted 3rd patent while also taking part in large medical cannabis study Canntab Therapeutics (CSE: PILL- OTCQB: CTABF) CFO Richard Goldstein joined Steve Darling from Proactive with news the Australian Patent Office has...

Canntab Granted 3rd Patent and Receives $400K Purchase Order in Australia!

- 3rd Patent Grant with Australia following the United States and Canada

- Initial Australian Purchase Order of $406,200 from our Australian partner Cann Global Limited

- Participation in Australia's Largest Cannabis Research Study

https://ca.finance.yahoo.com/news/alectra-working-night-restore-more-233400946.html

**p

*****na

Canntab Granted 3rd Patent and Receives $400K Purchase Order in Australia * 3rd Patent Grant with Australia following the United States and Canada * Initial Australian Purchase Order of $406,200 from our Australian partner Cann Global Limited * Participation in Australia's Largest Cannabis Research StudyTORONTO, March 9, 2021 /CNW/ - Canntab Therapeutics Limited (CSE: PIL...

We are kicking off March with a big announcement!

CANNTAB FULFILLS 80% OF ITS CONTRACT WITH MEDIPHARM LABS CORP.

Canntab has completed its 2nd (second) delivery of (2) (two) additional SKU's ordered by MediPharm Labs Corp ("MediPharm Labs") (TSX: LABS) (OTCQX: MEDIF) including 12.5mg CBD caplets (hard tablets in the shape of capsules) and 25mg CBD caplets for approximately $550,000.00.

https://canntab.ca/press-releases/

Canntab Therapeutics Dedicated to the research and development of hard pill, therapeutic formulations of cannabis.

CANNTAB BEGINS DELIVERY OF TABLETS TO MEDIPHARM

We have completed our first delivery of two (2) of a total of five (5) SKU's ordered by MediPharm Labs Corp!

https://ca.finance.yahoo.com/news/harborside-inc-announces-positive-preliminary-124700635.html

Canntab Begins Delivery of Tablets to MediPharm TORONTO, Dec. 1, 2020 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.

CANNTAB BURSTS OUT OF THE STARTING BLOCK WITH $1.3M ORDER!

Read more in this http://Equity.Guru article.

https://equity.guru/2020/12/01/canntab-therapeutics-pill-c-bursts-out-of-the-starting-blocks-with-1-3-million-sale/

Canntab Therapeutics’ (PILL.C) bursts out of the starting blocks with $1.3 million sale | Equity.Guru PILL is developing solid oral dose formulations of cannabis with a product line of cannabinoid (THC & CBD) and terpenoid blends in multiple doses and timed-release combinations

NEW VIDEO! Richard Goldstein, our Co-founder and CFO, and Larry Latowsky, our CEO, were on Proactive Investors with Steve Darling discussing our first shipment of tablets to Medipharm!

Check out the full video interview below.

https://www.youtube.com/watch?v=xx1PNVp1-Fo

Canntab Therapeutics hits major milestone as company makes first delivery to MediPharm Labs Canntab Therapeutics (CSE: PILL- OTCQB: CTABF) CEO Larry Latowski and CFO Richard Goldstein joined Steve Darling from Proactive with news the company has com...

Big News! Canntab Granted 1st US Patent Covering Multi-Layer (Bi-Layer) Tablets.

"Canntab expects this and future patents to be very valuable in the development of our strategic partnerships and alliances and in our efforts to secure worldwide distribution of our proprietary products," explains Mr. Latowsky, CEO.

https://www.newswire.ca/news-releases/canntab-granted-1st-us-patent-covering-multi-layer-bi-layer-tablets-896101347.html

Canntab Granted 1st US Patent Covering Multi-Layer (Bi-Layer) Tablets /CNW/ - Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene...

Press Release: Canntab Appoints Joshi Laxminarayan as Chief Scientific Officer.

https://tinyurl.com/yaaz9xhw

Canntab Appoints Joshi Laxminarayan as Chief Scientific Officer TORONTO, May 15, 2020 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN - News)(OTCQB:CTABF - News) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the appointment

Our soon to be Executive Chairman of the Board, Larry Latowsky, will be speaking at the Canaccord Genuity Cannabis Conference tomorrow at 9:20am.

You'll be able to join the conference through your browser.
Check out the press release for all the details.

http://tiny.cc/5whvoz

Canntab to Present at the Canaccord Genuity 2020 Virtual Cannabis Conference Canntab to Present at the Canaccord Genuity 2020 Virtual Cannabis Conference

It's our Birthday! We've been going strong for 4 years, and the future looks bright! Thank you to all of our supporters, we look forward to bringing our unique medical cannabinoid solutions to market in the coming months.
**p

We received our Cannabis Licence for Processing and Medical Sales, now we are moving into full-scale production of the full suite of our game changing medical cannabinoid solutions.
canntab.ca/press/
**p

We are exciting to announce that we've received our Cannabis Research License from Health Canada!
“Our Cannabis Research Licence will allow us to be prepared for when we receive our Standard Processing Licence and Sale” for Medical Purposes Licence, which we expect to receive shortly, by allowing us to do research and testing. Once we obtain our Standard Processing Licence and Sale for Medical Purposes Licence, we will have products ready for distribution and sale," explains Jeff Renwick, co-founder and CEO of Canntab. Mr. Renwick continues, “our facility is fully built-out and we are excited to prepare our final formulations for submission. We are equally excited with the prospect of continuing research and development in full force at our Markham facility, beginning with our proprietary Oral Dissolvable Tablet formulations which enter through the buccal cavity in the patient’s mouth.”
Check out our Press page on our website for the full release.
**p

🎉We submitted our Site Evidence Package to Health Canada at the end of December, and we are expecting receipt of our Cannabis License in the near future. This is an exciting for Canntab, we are bringing our vision to life, we will become the global leader in the production of solid oral dose therapeutic cannabis
In a short time, we will be transforming into full scale manufacturing and distribution of our game changing products.
**p

We are at MJ Biz Con in Las Vegas!! It's an exciting time in our companies evolution and we are hear with our partners from south of the border, drumming up business and staying connected.
2020 is going to be a big year for Canntab!
**p **pfarm **p **pcbd **poil *****na